Acid Reflux Disease Completed Phase 2 Trials for Lesogaberan (DB11920)

Indication	Status	Phase
DBCOND0034510 (Acid Reflux Disease)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00703534	Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms		Aluminum hydroxide (DB06723) Dimethicone (DB11074) Lesogaberan (DB11920) Magnesium hydroxide (DB09104) Silicon dioxide (DB11132)